Pacific Biosciences of California Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Hey everyone, good afternoon. Thanks for joining us at the Morgan Stanley Global Healthcare Conference today. I'm Tejas Savant, and I cover the life science tools and diagnostics sector here. Delighted to have Pacific Biosciences join us this afternoon. And representing the company, we have Christian Henry, CEO; and Susan Kim, CFO. Welcome to you both.
Before we get into the Q&A, just had a quick safe harbor to rattle off. Please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your sales rep.
So with that, Christian, welcome, again. Clearly, just to set the stage, I mean, there's been a transformation underway at PacBio since you took the CEO seat about a year ago. You have the SoftBank deal. You have the Invitae collaboration. Since then you've purchased Omniome and Circulomics and strengthened the commercial team, of course. So as you look ahead to 2022, could you outline for us what you think is the next leg of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
